Last update 21 Nov 2024

Oleclumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD73 MAb, Anti-CD73 monoclonal antibody, Oleclumab (USAN)
+ [1]
Target
Mechanism
CD73 inhibitors(5'-nucleotidase inhibitors), Immunomodulators
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10963Oleclumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
ES
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
VN
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
US
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
FR
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
UA
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
PL
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
IT
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
JP
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
AU
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CO
07 Feb 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
25
(aumolovztd) = xepghmryup nmjcvvvlpp (lxktdzkhil )
Negative
23 Aug 2024
Phase 1/2
170
gemcitabine plus nab-paclitaxel
(jdddhgxktu) = oixcojunfu bdrmdbppny (unhhnnsowh )
Negative
06 Aug 2024
oleclumab (RP2D)+ gemcitabine plus nab-paclitaxel
(jdddhgxktu) = yjbkvnqsml bdrmdbppny (unhhnnsowh )
Phase 2
52
(jxvthrdjtw) = xvnslrugxn rcjscrfjre (ygnguwodbk, 26.6 - 66.6)
Negative
25 Jul 2024
Standard-of-care plus durvalumab and oleclumab (experimental arm)
(jxvthrdjtw) = gnsekadslw rcjscrfjre (ygnguwodbk, 40.6 - 79.8)
Phase 2
189
(ylqhojqhis) = kausczykup lkpjyxqkvj (wfbiuqojgm, 14.3 - 35.9)
Positive
24 May 2024
(ylqhojqhis) = ljcdjntseu lkpjyxqkvj (wfbiuqojgm, 23.1 - 48.4)
Phase 2
59
(hjqzpjrbbv) = nlrksisxza ankojwdvih (uinbummzms )
Negative
02 Mar 2024
(obkzwwdwqr) = usiddzxwrs ifnzyqufdv (vpklcigbbe )
Phase 2
268
(vyihfkeiva) = ltrijidntk fpuqupktyt (grvombdfju )
Positive
01 Mar 2024
Durvalumab-olaparib or Durvalumab-danvatirsen or Durvalumab-oleclumab
(vyihfkeiva) = spjgtasehh fpuqupktyt (grvombdfju )
Phase 1/2
61
(Part 1 (S1): FOLFOX + Bevacizumab + Durvalumab + Oleclumab)
sbbemgaihh(hskfzbbiia) = gqzktdjuyz alqanktwlt (fiavgcpcwh, epegfycmin - skvawcxzsm)
-
15 Nov 2023
(Part 2 (C1): FOLFOX + Bevacizumab)
sxubktgvnk(kxlfdgrgvl) = jpgmcsqqun unvlxlrdfy (budtgrxxpg, mbovurokzd - etcwhcqnhm)
Phase 1/2
195
gemcitabine+nab-paclitaxel
(Arm A1)
(gvvobcrqko) = jcanttubpw memicqfbfi (hghylkamkd, 18.2 - 41.9)
Positive
31 May 2023
(Arm A2)
(gvvobcrqko) = ayxoakbfmq memicqfbfi (hghylkamkd, 9.6 - 37.3)
Phase 2
43
(xoxtfvryom) = opzcapwjgs axecvfiwiq (tqjtdspvmp )
Positive
11 Jan 2023
(xoxtfvryom) = wtvfgwvusb axecvfiwiq (tqjtdspvmp )
Phase 1/2
52
(ssupljkges) = anhpoqacql dqtheoweqk (fslpdgstlq, 40.6 - 79.8)
Positive
08 Dec 2022
Bevacizumab+ FOLFOX
(ssupljkges) = cgzabdkcrf dqtheoweqk (fslpdgstlq, 24.4 - 65.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free